Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP350 CAR-T for R/R EBV-Associated Lymphoid Neoplasms
NCT07306156Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GP350 CAR-T in Epstein-Barr virus-associated lymphoid neoplasm (EBV-LNP). Started Nov 2025; status: recruiting.
02
Drugs
GP350 CAR-T
03
Conditions
Epstein-Barr virus-associated lymphoid neoplasm (EBV-LNP)
Beyond the preview
Go deeper on NCT07306156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306156.